Clinical Trials Using Ramucirumab

Clinical trials are research studies that involve people. The clinical trials on this list are studying Ramucirumab. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-20 of 20
  • Targeted Treatment (Ramucirumab Plus Pembrolizumab) for Advanced Non-Small Cell Lung Cancer (A Lung-MAP Non-Matched Treatment Trial)

    This phase II Lung-MAP Non-Matched treatment trial studies how well ramucirumab and pembrolizumab work versus standard of care in treating patients with non-small cell lung cancer that is stage IV or has come back (recurrent). Ramucirumab is a monoclonal antibody that attaches to and inhibits a molecule called VEGFR-2. This may restrain new blood vessel formation therefore reducing nutrient supply to tumor which may interfere with tumor cell growth and expansion. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in standard of care chemotherapy for non-small cell lung cancer, such as docetaxel, gemcitabine hydrochloride, and pemetrexed, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ramucirumab and pembrolizumab together may work better in treating patients with non-small lung cancer compared to standard of care.
    Location: 759 locations

  • Carboplatin and Paclitaxel with or without Ramucirumab in Treating Patients with Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery

    This randomized phase II trial studies how well carboplatin and paclitaxel with or without ramucirumab work in treating patients with thymic cancer that has spread to other places in the body, has come back, or cannot be removed by surgery. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as ramucirumab, may interfere with the ability of tumor cells to grow and spread. It is not yet known if giving carboplatin and paclitaxel with or without ramucirumab will work better in treating patients with thymic cancer.
    Location: 179 locations

  • Olaparib and Ramucirumab in Treating Patients with Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery

    This phase I / II trial studies the side effects and best dose of olaparib when given together with ramucirumab and how well they work in treating patients with gastric or gastroesophageal junction cancer that has spread to other places in the body (metastatic), has come back (recurrent), or cannot be removed by surgery (unresectable). Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as ramucirumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving olaparib and ramucirumab may work better in treating patients with gastric or gastroesophageal junction cancer compared to ramucirumab and paclitaxel (a chemotherapy drug) or ramucirumab alone.
    Location: 30 locations

  • A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein

    The purpose of this study is to evaluate the safety and efficacy of ramucirumab in participants with hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein. Participants will be randomized to ramucirumab or placebo in a 2:1 ratio (Main Global Cohort and China Maximized Extended Enrollment [ME2] Cohort). Participants may also receive ramucirumab if eligible to be enrolled in Open-Label Expansion (OLE) Cohort.
    Location: 6 locations

  • A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G / GEJ) (Morpheus-Gastric Cancer)

    A Phase Ib / II, open label, multi-center, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in patients with locally advanced unresectable or metastatic G / GEJ cancer (hereafter referred to as gastric cancer). Two cohorts will be enrolled in parallel in this study: the second-line (2L) Cohort will consist of patients with gastric cancer who have progressed after receiving a platinum-containing or fluoropyrimide-containing chemotherapy regimen in the first-line setting, and the first-line (1L) Cohort will consist of patients with gastric cancer who have not received prior chemotherapy in this setting. In each cohort, eligible patients will be assigned to one of several treatment arms.
    Location: 6 locations

  • Ramucirumab and Irinotecan Hydrochloride in Treating Patients with Metastatic or Locally Advanced Gastric or Gastroesophageal Junction Cancer

    This phase II trial studies how well ramucirumab and irinotecan hydrochloride work in treating patients with gastric or gastroesophageal junction cancer that has spread to other parts of the body (metastatic). Monoclonal antibodies, such as ramucirumab may interfere with the ability of cancer cells to grow and spread. Irinotecan hydrochloride may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving ramucirumab and irinotecan hydrochloride may be a better treatment for patients with metastatic or advanced gastric or gastroesophageal junction cancer.
    Location: 4 locations

  • Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma

    This study will evaluate the combination of Nivolumab and Ramucirumab in patients with previously-treated mesothelioma.
    Location: 3 locations

  • Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

    The primary objective of the study is to evaluate the efficacy of osimertinib plus ramucirumab versus osimertinib alone using progression free survival (PFS). Events associated with PFS include: disease progression per RECIST 1.1 and death due to any cause. A total of 150 patients will be enrolled and randomized in a 2:1 fashion (osimertinib plus ramucirumab vs. osimertinib) to the two treatment arms according to the following stratification factors: types of epidermal growth factor receptor (EGFR) mutations and presence of brain metastasis.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Ramucirumab and Atezolizumab in Treating Patients with Non-small Cell Lung Cancer

    This phase II trial studies how well ramucirumab and atezolizumab work in treating patients with non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as ramucirumab and atezolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri

  • TAS 102 and Ramucirumab in Treating Patients with Stage IV or Recurrent Gastric or Gastroesophageal Junction Cancer

    This phase II trial studies the side effects and how well TAS 102 and ramucirumab work in treating patients with gastric or gastroesophageal junction cancer that is stage IV or that has come back. TAS 102 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as ramucirumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving TAS 102 and ramucirumab may work better in treating patients with gastric or gastroesophageal junction cancer.
    Location: Moffitt Cancer Center, Tampa, Florida

  • Ramucirumab and Pembrolizumab in Treating Patients with Incurable Recurrent or Metastatic Head and Neck Squamous Cell Cancer

    This phase I / II trial studies the side effects and best dose of ramucirumab when given together with pembrolizumab and how well it works in treating patients with head and neck squamous cell cancer that has come back (recurrent) or has spread to other places in the body (metastatic) for which no treatment is currently available (incurable). Monoclonal antibodies, such as ramucirumab, may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri

  • Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma

    This is a single-arm phase I / Ib study of crenolanib combined with ramucirumab / paclitaxel as second line therapy for patients with advanced / metastatic adenocarcinoma of the esophagus, GEJ or stomach. Patients will be enrolled in two phases; dose escalation phase and dose expansion phase.
    Location: Memorial Sloan Kettering Cancer Center, New York, New York

  • Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers

    This is a nonrandomized, open-label, single group assignment, safety, tolerability and pharmacokinetic (PK) study to determine the MTD and optimal dosing regimen of Oraxol in combination with ramucirumab.
    Location: Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas

  • A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors

    The main purpose of this study is to evaluate the safety and tolerability of anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody LY3300054 in participants with advanced refractory solid tumors.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Ramucirumab and Nab-Paclitaxel in Treating Patients with Previously Treated Stage IV Non-small Cell Lung Cancer

    This phase II clinical trial studies the side effects of ramucirumab and nab-paclitaxel and to see how well they work in treating patients with previously treated stage IV non-small cell lung cancer. Monoclonal antibodies, such as ramucirumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ramucirumab and nab-paclitaxel together may work better in treating patients with previously treated stage IV non-small cell lung cancer.
    Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania

  • Ramucirumab in Treating Patients with Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery

    This phase II trial studies how well ramucirumab works in treating patients with previously treated biliary cancers that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or have spread to other places in the body (metastatic) and cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as ramucirumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Personalized Antibodies in Treating Patients with Metastatic Stomach or Gastroesophageal Junction Cancer

    This pilot phase II trial studies personalized antibodies in treating patients with stomach or gastroesophageal junction cancer that has spread to other parts of the body. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies may block tumor growth in different ways by targeting certain cells. Testing tumor tissue for gene mutations and protein expression patterns and using drugs that target the specific profile of the tumor, may work better than standard chemotherapy in treating patients with stomach or gastroesophageal junction cancer.
    Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois

  • Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

    This study will determine the pharmacodynamically-active dose of gevokizumab and the tolerable dose and preliminary efficacy of gevokizumab in combination with the standard of care anti-cancer therapy in patients with metastatic colorectal cancer, metastatic gastroesophageal cancer and metastatic renal cell carcinoma.
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

  • MM-398 and Ramucirumab in Treating Patients with Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

    This phase I / II trial studies the side effects and best dose of MM-398 and ramucirumab in treating patients with gastric cancer or gastroesophageal junction adenocarcinoma. MM-398 contains a chemotherapy drug called irinotecan, which in its active form interrupts cell reproduction. MM-398 builds irinotecan into a container called a liposome which may be able to release the medicine slowly over time to reduce side effects and increase its ability to kill tumor cells. Immunotherapy with monoclonal antibodies, such as ramucirumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving MM-398 and ramucirumab together may work better in treating patients with gastric cancer or gastroesophageal junction adenocarcinoma.
    Location: USC / Norris Comprehensive Cancer Center, Los Angeles, California

  • Biomarker-Driven Therapy and Immunotherapy in Screening Participants with Recurrent or Stage IV Non-Small Cell Lung Cancer (The Expanded Lung-MAP Screening Trial)

    This expansion of the screening and multi-sub-study Lung-MAP trial is motivated by the changing landscape due to progress in the development of immunotherapies. The Lung-MAP trial was originally opened in June of 2014 for second-line treatment of participants with stage IV squamous lung cancer or squamous lung cancer that has come back (recurrent). The trial was amended to allow all participants with previously-treated stage IV or recurrent squamous lung cancer in 2015. The study is now expanding to allow participants with all types of previously-treated stage IV or recurrent non-small cell lung cancer. The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned in order to compare new targeted cancer therapy designed to block the growth and spread of cancer, with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes “non-match” sub-studies which will include all screened participants not eligible for any of the biomarker-driven sub-studies.
    Location: 644 locations